Pyrrothiogatain
Based on 1 publication(s) in Google Scholar
Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC50 of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.61%
- CAS. Nr.: 477888-48-5
- Formel: C11H11NO2S
- Molecular Weight:221.28
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Aging Compound Library
HY-L034
-
Differentiation Inducing Compound Library
HY-L038
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Mitochondrial Protection Compound Library
HY-L144
-
Antihypertensive Compound Library
HY-L145
-
Protease Inhibitor Library
HY-L147
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
Publications Citing Use of MedChemExpress (MCE) Pyrrothiogatain
MoreAlle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
MoreAlle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
GATA3 54.7 μM (IC50) |
IL-4 |
IL-5 |
IL-6 |
IL-13 |
ACE |
Pyrrothiogatain (50-100 μM) inhibits the DNA-binding activity of GATA3[1].
Pyrrothiogatain (0-100 μM, 3 days) does not influence cell viability in Jurkat cells[1].
Pyrrothiogatain (10-30 μM) suppresses GATA3-dependent transcriptional activation of the IL-5 promoter in HEK293T cells[1].
Pyrrothiogatain (30-80 μM, 5 days) inhibits Th2 cell differentiation in CD4+ T cells[1].
Pyrrothiogatain (80 μM, 2 days) inhibits GATA3 binding to Th2 cytokine gene locus in CD4+ T cells[1].
Pyrrothiogatain (50 μM, 4 days) decreases cell ount in both NT and GATA-3 knockout 3T3L1 cells[2].
Pyrrothiogatain (50 μM) reduces IL-6 and TNF-α levels in 3T3L-1 preadipocytes[2].
Pyrrothiogatain (50-500 μM) reduces ACE2 and in HEK293T cells[3].
Pyrrothiogatain (500 μM, 48 h) reduces SARS-CoV-2 viral load in Calu-3 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD4+ T cells
-
Concentration:30 and 80 μM
-
Incubation Time:5 days
-
Result:Inhibited generation of IL-4-, IL-5-, and IL-13-producing Th2 cells.
Decreased production and mRNA expression of IL-4, IL-5 and IL-13.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cdc42+/+Foxp3YFP-Cre mice with MC38 tumor[4]
-
Dosage:60 mg/kg
-
Administration:Intraperitoneally injection, once a day
-
Result:Reduced tumor volume.
Chemical Information
-
CAS. Nr. 477888-48-5
-
Appearance Solid
-
Molecular Weight 221.28
-
Formel C11H11NO2S
-
Color Light yellow to orange
-
SMILES
O=C(C1=C(N2C(C)=CC=C2C)C=CS1)O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep
Tfam-mediated metabolic perturbation in RORγt+ lymphocytes impacts intestinal tissue homeostasis and promotes GATA3+RORγt+ innate lymphoid cells. [Abstract]2026 Feb 24;45(2):116952. PMID: 41678335
Lösungsmittel & Löslichkeit
DMSO : 125 mg/mL (564.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Nomura S, et al. Pyrrothiogatain acts as an inhibitor of GATA family proteins and inhibits Th2 cell differentiation in vitro. Sci Rep. 2019 Nov 22;9(1):17335. [Content Brief]
[2]. Almuraikhy S, et al. Targeted Inhibition of GATA-3 by Pyrrothiogatain: Implications for Adipocyte Biology and Inflammatory Response. Cells. 2025 Jan 10;14(2):100. [Content Brief]
[3]. Israeli M, et al. Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. Nat Commun. 2022 Apr 25;13(1):2237. [Content Brief]
[4]. Kalim KW, et al. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity. J Immunother Cancer. 2022 Nov;10(11):e004806. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.5192 mL | 22.5958 mL | 45.1916 mL | 112.9790 mL |
| 5 mM | 0.9038 mL | 4.5192 mL | 9.0383 mL | 22.5958 mL | |
| 10 mM | 0.4519 mL | 2.2596 mL | 4.5192 mL | 11.2979 mL | |
| 15 mM | 0.3013 mL | 1.5064 mL | 3.0128 mL | 7.5319 mL | |
| 20 mM | 0.2260 mL | 1.1298 mL | 2.2596 mL | 5.6490 mL | |
| 25 mM | 0.1808 mL | 0.9038 mL | 1.8077 mL | 4.5192 mL | |
| 30 mM | 0.1506 mL | 0.7532 mL | 1.5064 mL | 3.7660 mL | |
| 40 mM | 0.1130 mL | 0.5649 mL | 1.1298 mL | 2.8245 mL | |
| 50 mM | 0.0904 mL | 0.4519 mL | 0.9038 mL | 2.2596 mL | |
| 60 mM | 0.0753 mL | 0.3766 mL | 0.7532 mL | 1.8830 mL | |
| 80 mM | 0.0565 mL | 0.2824 mL | 0.5649 mL | 1.4122 mL | |
| 100 mM | 0.0452 mL | 0.2260 mL | 0.4519 mL | 1.1298 mL |
Powered by Bioz